06.08.15
Bioness Inc. has rolled out its StimRouter system, an implantable neuromodulation device to treat chronic, intractable pain of peripheral nerve origin as an adjunct to other modes of therapy (e.g., medications). StimRouter received clearance from the U.S. Food and Drug Administration in February and, according to the company, is the only implantable neuromodulation device indicated to treat chronic pain of peripheral nerve origin.
“The commercial launch of StimRouter for peripheral pain positions Bioness to strategically build on the success of our neuromodulation portfolio,” said Bioness President and CEO Todd Cushman. “In addition to pain applications, we started a pilot study for overactive bladder in February and we anticipate expanding to other commercial markets in the future.”
As a minimally invasive device designed to reduce pain by specifically targeting the affected peripheral nerve, StimRouter is—company bigwigs claim—a cost-effective alternative to injections, ongoing medication regiments and complex surgeries. According to company estimates, an estimated 50 million people suffer from chronic pain, which contributes an additional $150 billion in annual costs to the U.S. healthcare system.
StimRouter consists of an implanted lead, external pulse transmitter (EPT) and conductive electrode, controlled by a small, hand-held wireless control unit. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. Each system is programmed at the direction of the physician to meet patient requirements.
Valencia, Calif.-based Bioness makes external and implantable functional electrical stimulation systems, robotic systems and software-based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders and orthopedic injuries.
“The commercial launch of StimRouter for peripheral pain positions Bioness to strategically build on the success of our neuromodulation portfolio,” said Bioness President and CEO Todd Cushman. “In addition to pain applications, we started a pilot study for overactive bladder in February and we anticipate expanding to other commercial markets in the future.”
As a minimally invasive device designed to reduce pain by specifically targeting the affected peripheral nerve, StimRouter is—company bigwigs claim—a cost-effective alternative to injections, ongoing medication regiments and complex surgeries. According to company estimates, an estimated 50 million people suffer from chronic pain, which contributes an additional $150 billion in annual costs to the U.S. healthcare system.
StimRouter consists of an implanted lead, external pulse transmitter (EPT) and conductive electrode, controlled by a small, hand-held wireless control unit. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. Each system is programmed at the direction of the physician to meet patient requirements.
Valencia, Calif.-based Bioness makes external and implantable functional electrical stimulation systems, robotic systems and software-based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders and orthopedic injuries.